Boundless Bio Q3 net loss $16.5M; cash $167.1M, runway into Q4 2026

Boundless Bio, Inc.

2024-Q3 EPS reported -$3.22

Net loss of $16.5M for Q3 2024 vs $13.2M in Q3 2023; R&D expenses $14.1M.
Cash, cash equivalents, and short-term investments total $167.1M as of Sept 30, 2024.
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP trials; initial proof-of-concept data expected H2 2025.
Analytical validation for proprietary ecDNA diagnostic ECHO presented at ESMO September 2024.
G&A expenses $4.6M vs $3.3M year-over-year; general operating cash runway into Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.